SCHEMBL5768636

SCHEMBL5768636

CCCC(=O)Nc1cnccc1O

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.49
KDM6B O15054 4/20 0.48
KDM4C Q9H3R0 4/20 0.48
KDM4D Q6B0I6 2/20 0.46
EGLN3 Q9H6Z9 1/20 0.46
ALDH1A1 P00352 1/20 0.45
TP53 P04637 1/20 0.45
POLB P06746 2/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
EP300 Q09472 1/20 0.43
AAK1 Q2M2I8 1/20 0.43
HTT P42858 1/20 0.43
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20569247 0.80 CA1 (0.45) KDM6BKDM4CKDM4DEGLN3
SCHEMBL21647181 0.79 TSHR (0.50) KDM4CALDH1A1LMNAGAA
SCHEMBL30508987 0.79 TSHR (0.50) KDM4CALDH1A1LMNAGAA
SCHEMBL6635013 0.79 PARP14 (0.48) MAPK1KDM6BKDM4CKDM4DEGLN3
SCHEMBL3194739 0.78 MAPT (0.47) MAPK1KDM4CKDM4DALDH1A1TP53
SCHEMBL19154135 0.77 MTNR1B (0.49) MAPK1ALDH1A1POLBLMNAGAA
SCHEMBL27145744 0.76 KDM4C (0.43) KDM6BKDM4CKDM4DEGLN3ALDH1A1
SCHEMBL29721986 0.76 MAPK1 (0.69) MAPK1ALDH1A1LMNAGAAEP300
SCHEMBL5536448 0.76 MAPK1 (0.69) MAPK1ALDH1A1LMNAGAAEP300
SCHEMBL19308412 0.76 ALDH1A1 (0.50) MAPK1ALDH1A1POLBLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7148232-B2 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-12-12 US disclosed
EP-1380587-B1 Oxazolo, thiazolo and selenazolo [4,5-c]naphthyridine-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES CO (US) 2006-03-15 EP disclosed
US-20050026943-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2005-02-03 US disclosed
US-6809203-B2 IMMUNOMODULATORS; INDUCING CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON-ALPHA AND/OR TUMOR NECROSIS FACTOR-ALPHA 3M INNOVATIVE PROPERTIES COMPANY 2004-10-26 US disclosed
US-20040122041-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2004-06-24 US disclosed
US-6703402-B2 IMMUNOMODULATORS; INDUCERS OF CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON AND/OR TUMOR NECROSIS FACTOR; ANTITUMOR AGENTS, VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2004-03-09 US disclosed
EP-1380587-A2 Oxazolo, thiazolo and selenazolo (4,5-c)-quinoline-4-amines and analogs thereof 3M Innovative Properties Company (US) 2004-01-14 EP disclosed
US-6677334-B2 IMMUNOMODULATORS, INDUCE CYTOKINE BIOSYNTHESIS, AND ANTINEOPLASTIC AGENTS 3M INNOVATIVE PROPERTIES COMPANY 2004-01-13 US disclosed
US-20030195224-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-10-16 US disclosed
US-6627640-B2 Viricides; anticancer agents 3M INNOVATIVE PROPERTIES COMPANY 2003-09-30 US disclosed
EP-1100802-B1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLINE-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2003-09-24 EP disclosed
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-03-06 US disclosed
US-6440992-B1 ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; USEFUL FOR THERAPY OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY 2002-08-27 US disclosed
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2002-06-13 US disclosed
US-6323200-B1 THE COMPOUNDS ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT THE T-HELPER-TYPE 2 IMMUNE RESPONSE. 3M INNOVATIVE PROPERTIES COMPANY 2001-11-27 US disclosed
EP-1100802-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M Innovative Properties Company (US) 2001-05-23 EP disclosed
US-6110929-A IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-08-29 US disclosed
WO-2000006577-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MAPK1 2827/4885KDM6B 3126/4885KDM4C 1818/4885
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MAPK1 2827/4885KDM6B 3126/4885KDM4C 1818/4885
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MAPK1 2827/4885KDM6B 3126/4885KDM4C 1818/4885
US-20030195224-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4- amines and analogs thereof IFNG, THPO, IL2 MAPK1 2827/4885KDM6B 3126/4885KDM4C 1818/4885
US-20050026943-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, IL2, IRF3 MAPK1 2201/4885KDM6B 3530/4885KDM4C 2005/4885
US-20040122041-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MAPK1 2827/4885KDM6B 3126/4885KDM4C 1818/4885
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 MAPK1 2827/4885KDM6B 3126/4885KDM4C 1818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.